Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Denali Therapeutics Inc (DNLI)

Denali Therapeutics Inc (DNLI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,109,408
  • Shares Outstanding, K 145,276
  • Annual Sales, $ 0 K
  • Annual Income, $ -422,770 K
  • EBIT $ -515 M
  • EBITDA $ -543 M
  • 60-Month Beta 1.33
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.99

Options Overview Details

View History
  • Implied Volatility 91.88% ( +10.70%)
  • Historical Volatility 47.71%
  • IV Percentile 78%
  • IV Rank 53.10%
  • IV High 132.13% on 04/16/25
  • IV Low 46.31% on 01/21/25
  • Put/Call Vol Ratio 0.00
  • Today's Volume 78
  • Volume Avg (30-Day) 86
  • Put/Call OI Ratio 0.47
  • Today's Open Interest 1,878
  • Open Int (30-Day) 1,867

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.74
  • Number of Estimates 13
  • High Estimate -0.43
  • Low Estimate -0.93
  • Prior Year -0.59
  • Growth Rate Est. (year over year) -25.42%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.41 +8.28%
on 06/23/25
15.38 -5.56%
on 07/10/25
-0.67 (-4.41%)
since 06/11/25
3-Month
12.30 +18.05%
on 04/14/25
16.97 -14.44%
on 05/02/25
+1.82 (+14.33%)
since 04/11/25
52-Week
10.57 +37.37%
on 04/07/25
33.33 -56.44%
on 11/11/24
-8.57 (-37.12%)
since 07/11/24

Most Recent Stories

More News
Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)

DNLI : 14.52 (-5.41%)
Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome

DNLI : 14.52 (-5.41%)
Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program

DNLI : 14.52 (-5.41%)
Why You Shouldn't Bet Against Denali (DNLI) Stock

One stock that might be an intriguing choice for investors right now is Denali Therapeutics Inc. DNLI. This is because this security in the Medical - Biomedical and Genetics space is seeing solid earnings...

DNLI : 14.52 (-5.41%)
Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

DNLI : 14.52 (-5.41%)
Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa

DNLI : 14.52 (-5.41%)
Denali Therapeutics Announces Upcoming Presentations on Hunter Syndrome (MPS II) and TransportVehicle™ Enabled Investigational Therapeutic Tividenofusp Alfa at the 2025 WORLDSymposium™

DNLI : 14.52 (-5.41%)
Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases

DNLI : 14.52 (-5.41%)
Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)

DNLI : 14.52 (-5.41%)
Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

DNLI : 14.52 (-5.41%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Denali Therapeutics, a biopharmaceutical company, is developing a wide and innovative portfolio of targeted therapeutic candidates, which are engineered to cross the blood-brain barrier for neurodegenerative diseases. It has 5 clinical-stage programs, a leucine-rich repeat kinase 2 inhibitor program...

See More

Key Turning Points

3rd Resistance Point 16.09
2nd Resistance Point 15.72
1st Resistance Point 15.12
Last Price 14.52
1st Support Level 14.15
2nd Support Level 13.78
3rd Support Level 13.18

See More

52-Week High 33.33
Fibonacci 61.8% 24.64
Fibonacci 50% 21.95
Fibonacci 38.2% 19.26
Last Price 14.52
52-Week Low 10.57

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar